Definitive study shows no association between ARID1A mutation status and clinical outcome in endometriosis-related ovarian cancers^‡.

ABSTRACT: The ARID1A tumour suppressor protein is a component of the SWI/SNF chromatin remodelling complex, which is mutated in approximately 20% of all human cancers. ARID1A mutational status is considered to hold prognostic significance in a range of solid malignancies, yet in endometriosis-related ovarian carcinomas there has been a lack of clarity of its prognostic role. Moreover, the relationship between ARID1A status and immune infiltrate is also poorly understood. In a recent issue of The Journal of Pathology, a large comprehensive study by Heinze, Nazeran et al addressed these areas by reviewing 1,623 endometriosis-associated ovarian carcinomas and correlating ARID1A status using standardised immunohistochemistry to infer mutation status, with comprehensive clinicopathological features, mism

SUBMITTER: Khalique S 

PROVIDER: S-EPMC9540905 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature